KBC Group NV increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 54.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the ...
JMP Securities reiterated their market outperform rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report report published on Friday,Benzinga reports. They ...
16h
Investor's Business Daily on MSNStocks Generating Improved Relative Strength: Protagonist TherapeuticsProtagonist Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results